Brian Bolwell, MD, Cleveland Clinic, discussed how all the information they're finding out about myeloid malignancies is very important, but also complex so making broad statements is challenging.
Regarding progress, Bolwell stated, "As my role as director of the Cleveland Clinic, we're very concerned about healthcare economics and showing value, and ASH is at the forefront of trying to publicize the challenge of the ongoing challenge of the ongoing cost of targeted therapies."
